Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study.
Victor S WangJustin KosmanHsiangkuo YuanClinton G LauritsenStephen ShrewsburySheena K AuroraMary HopkinsStephen SilbersteinPublished in: Headache (2023)
Patients receiving intravenous DHE by the Jefferson Headache Center inpatient headache protocol had significantly reduced pain severity at discharge. No clinically significant cardiac or electrocardiogram abnormalities were detected in patients with elevated (or low) atherosclerotic cardiovascular disease risk. Repetitive intravenous DHE used by our protocol was safe in refractory chronic migraine patients.
Keyphrases
- cardiovascular risk factors
- cardiovascular disease
- randomized controlled trial
- high dose
- end stage renal disease
- high frequency
- chronic kidney disease
- newly diagnosed
- ejection fraction
- chronic pain
- systematic review
- prognostic factors
- type diabetes
- peritoneal dialysis
- palliative care
- left ventricular
- mental health
- heart failure
- coronary artery disease
- double blind
- postoperative pain